Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Moderate Buy” by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $45.8462.

Several brokerages have issued reports on JANX. JonesTrading cut their price objective on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and cut their price objective for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Guggenheim cut their price objective on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Truist Financial upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, May 4th.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the sale, the vice president owned 32,270 shares of the company’s stock, valued at $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $34,000. Osaic Holdings Inc. increased its holdings in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $51,000. Tower Research Capital LLC TRC increased its holdings in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the period. Finally, Winthrop Capital Management LLC bought a new position in shares of Janux Therapeutics during the third quarter worth approximately $106,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Trading Down 2.9%

JANX stock opened at $13.36 on Friday. The firm has a market capitalization of $814.69 million, a PE ratio of -7.26 and a beta of 2.53. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The business’s 50 day simple moving average is $14.50 and its 200 day simple moving average is $15.56.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. As a group, sell-side analysts predict that Janux Therapeutics will post -1.7 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.